ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
66,260.94
0.10%
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs Yen
157.405
0.00%
Brent Oil
82.275
0.00%
Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Nektar Therapeutics (NKTR)

  7. Nektar Therapeutics (NKTR) ニュース

NKTR

Nektar Therapeutics (NKTR)

Nektar Therapeutics
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:NKTR
日付受信時刻ニュースソース見出しコード企業名
2024/06/1507 : 02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
2024/06/1505 : 11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
2024/06/1222 : 30PR Newswire (US)Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024NASDAQ:NKTRNektar Therapeutics
2024/06/0705 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
2024/06/0613 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NKTRNektar Therapeutics
2024/06/0606 : 30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:NKTRNektar Therapeutics
2024/05/3107 : 00PR Newswire (US)Nektar Management to Present at Upcoming Investor ConferencesNASDAQ:NKTRNektar Therapeutics
2024/05/2905 : 51Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:NKTRNektar Therapeutics
2024/05/2110 : 14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
2024/05/2110 : 13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
2024/05/2110 : 12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
2024/05/1805 : 25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
2024/05/1805 : 22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
2024/05/1805 : 14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NKTRNektar Therapeutics
2024/05/1405 : 36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
2024/05/1005 : 20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
2024/05/1005 : 15PR Newswire (US)Nektar Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:NKTRNektar Therapeutics
2024/05/0307 : 00PR Newswire (US)Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
2024/03/2303 : 00PR Newswire (US)Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual ConferenceNASDAQ:NKTRNektar Therapeutics
2024/03/0607 : 11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NKTRNektar Therapeutics
2024/03/0523 : 00PR Newswire (US)Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia AreataNASDAQ:NKTRNektar Therapeutics
2024/03/0506 : 20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
2024/03/0506 : 15PR Newswire (US)Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:NKTRNektar Therapeutics
2024/03/0422 : 40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NKTRNektar Therapeutics
2024/03/0422 : 30PR Newswire (US)Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGXNASDAQ:NKTRNektar Therapeutics
2024/02/2808 : 00PR Newswire (US)Nektar Management to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:NKTRNektar Therapeutics
2024/02/2708 : 00PR Newswire (US)Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial MarketsNASDAQ:NKTRNektar Therapeutics
2024/02/2310 : 19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
2024/02/2310 : 17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
2024/02/2310 : 16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NKTRNektar Therapeutics
 Showing the most relevant articles for your search:NASDAQ:NKTR

最近閲覧した銘柄

NYSE
NKE
Nike
USOTC
ADDYY
Adidas (QX)
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
NYSE
KO
Coca Cola
NYSE
JPM
JP Morgan Chase
NASDAQ
QQQ
Invesco QQQ Trust Series 1
NYSE
MCD
McDonalds
NYSE
XOM
Exxon Mobil
CCOM
US100
US Tech 100
NYSE
BAC
Bank of America
AMEX
XLF
Financial Select Sector
CCOM
US30
US 30
NYSE
DIS
Walt Disney
NASDAQ
AAPL
Apple
USOTC
BNPQY
BNP Paribas (QX)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有